<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599284</url>
  </required_header>
  <id_info>
    <org_study_id>VCP1-Ⅱ-01</org_study_id>
    <nct_id>NCT03599284</nct_id>
  </id_info>
  <brief_title>The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel</brief_title>
  <official_title>The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu vcare pharmaceutical technology co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu vcare pharmaceutical technology co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled,
      dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and
      planned percutaneous coronary intervention （PCI） will be randomized after informed consent,
      in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg
      loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading
      followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by
      7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28
      days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel
      antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease
      during and after PCI compared with clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">July 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>Inhibition of platelet aggregation will be assessed by Verifynow System</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Platelet Aggregation Inhibitors</condition>
  <arm_group>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 5mg</intervention_name>
    <description>Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days</description>
    <arm_group_label>Experimental group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 6mg</intervention_name>
    <description>Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days</description>
    <arm_group_label>Experimental group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicagrel 7.5mg</intervention_name>
    <description>Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days</description>
    <arm_group_label>Experimental group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18-75.

          -  Weight ≥ 50 kg

          -  Patients with coronary atherosclerotic heart disease diagnosed clinically and planned
             percutaneous coronary intervention

          -  Patients with ability and willingness to sign informed consent and adherence to trial
             protocol.

        Exclusion Criteria:

          -  Hemorrhagic symptoms (such as hematemesis, melena, severe or recurrent epistaxis,
             hemoptysis, marked hematuria, gastrointestinal bleeding, or intracranial hemorrhage),
             or suspected vascular malformations (such as aneurysms), or abnormal bleeding history
             (such as abnormal hemorrhage attributed to tooth extraction), himself or his immediate
             family with coagulation or bleeding disorders (such as hemophilia);

          -  Non-ST-segment elevation acute coronary syndrome (&lt;2h emergency PCI), or ST-segment
             elevation myocardial infarction within 7 days;

          -  Patients with suspected aortic dissection;

          -  Patients with negative coronary Computed Tomography angiography（CTA）(coronary CTA
             depending on investigator);

          -  Patients with severe disease and life expectancy &lt;1 year;

          -  Patients with acute peptic ulcer;

          -  History of hemorrhagic stroke or history of ischemic stroke within 6 months before
             screening and a definite diagnosis of structural abnormalities in the central nervous
             system;

          -  Patients with uncontrolled high blood pressure (systolic blood pressure ≥ 180 mmHg or
             diastolic blood pressure ≥ 110 mmHg) after drug treatment during screening;

          -  One of the following conditions: cardiogenic shock, chronic congestive heart with
             failure New York Heart Association (NYHA) grade ≥ III grade or left ventricular
             ejection fraction determined by echocardiography &lt; 35%, hypotension (systolic pressure
             &lt; 90 mmHg and or diastolic pressure &lt; 60 mmHg), severe arrhythmias (including
             high-degree atrioventricular block, sick sinus syndrome, persistent ventricular
             tachycardia), severe pulmonary insufficiency, pulmonary embolism, and hepatic
             insufficiency (ALT or AST caused by non-cardiac diseases exceeding the upper limit of
             normal by more than 3 times), severe renal insufficiency (eGFR &lt; 30 ml/min),
             cirrhosis;

          -  Patients Received P2Y12 receptor antagonist and Ⅱb/IIIa receptor inhibitor, oral
             anticoagulant (warfarin, rivaroxaban, dabigatran, etc.) within 14 days before
             screening;

          -  Prolonged cardiopulmonary resuscitation (more than 10 minutes) or severe trauma within
             2 weeks before screening;

          -  Patients plan to undergo another surgery within 1 month after participating in this
             trial，or plan to undergo PCI procedure performed several times during the test (except
             for the end of the safety follow-up);

          -  History of severe allergies, non-allergic drug reactions or allergies to 2 or more
             drugs (including contrast agents), or known allergies to the similar drugs
             (clopidogrel, ticagrelor) as the study drug or contraindication of aspirin;

          -  Patients with mental disorders or alcohol dependence;

          -  Patients being receiving any experimental medicine or experimental medical devices;

          -  Prothrombin time (PT)&gt; 1.3 times the upper limit of normal or international normalized
             ratio (INR)&gt; 2.0;

          -  Platelet count (PLT) &lt; 100×10^9/L or &gt; 600×10^9/L;

          -  Hemoglobin &lt; 10g/dL;

          -  Patients who cannot tolerate dual antiplatelet therapy for 28 days;

          -  Female of reproductive age with positive blood pregnancy test;

          -  Female with gestational intention or in lactation;

          -  Other unsuitable conditions considered by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical Universily</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhongshan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital of Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the General Hospital of Shenyang Military Region of The Chinese People's Liberation Army（The General Hospital of Shenyang Military）</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110134</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qinghai Provincial People's Hospital</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <zip>810007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuncheng Central Hospital</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjing</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

